However, approximately one in three patients with AML relapse after allogenic stem cell transplant. DLI is a follow-on treatment that can help stave off or treat relapse. It involves an infusion ...

The case involves a patient who, nine years after receiving a stem cell transplant for acute myeloid leukemia (AML), developed a new, aggressive blood cancer originating from donor cells.

Allogenic hematopoietic stem cell transplant is an important therapy for AML patients. In 2024 alone, 20,800 new cases of AML were diagnosed and the five-year survival rate for patients is 31.9% ...

The researchers looked at stem cells from AML patients at the Stanford Medical Center to see if they also expressed CD47. “They all did,” says Weissman. After demonstrating in cell culture experiments ...